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Abstract
Background
Chronic kidney disease (CKD) may be common among individuals living in sub-Saharan
Africa due to the confluence of CKD risk factors and genetic predisposition.
Methods
We ascertained the prevalence of CKD and its risk factors among a sample of 3,686 partici-
pants of a population-based HIV trial in rural Uganda and Kenya. Prevalent CKD was
defined as a serum creatinine-based estimated glomerular filtration rate <60 mL/min/1.73m2
or proteinuria (urine dipstick�1+). We used inverse-weighting to estimate the population
prevalence of CKD, and multivariable log-link Poisson models to assess the associations of
potential risk factors with CKD.
Results
The estimated CKD prevalence was 6.8% (95% CI 5.7–8.1%) overall and varied by region,
being 12.5% (10.1–15.4%) in eastern Uganda, 3.9% (2.2–6.8%) in southwestern Uganda
and 3.7% (2.7–5.1%) in western Kenya. Risk factors associated with greater CKD preva-
lence included age�60 years (adjusted prevalence ratio [aPR] 3.5 [95% CI 1.9–6.5] com-
pared with age 18–29 years), HIV infection (aPR 1.6 [1.1–2.2]), and residence in eastern
Uganda (aPR 3.9 [2.6–5.9]). However, two-thirds of individuals with CKD did not have HIV,
diabetes, or hypertension as risk factors. Furthermore, we noted many individuals who did
not have proteinuria had dipstick positive leukocyturia or hematuria.
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Conclusion
The prevalence of CKD is appreciable in rural East Africa and there are considerable
regional differences. Conventional risk factors appear to only explain a minority of cases,
and leukocyturia and hematuria were common, highlighting the need for further research
into understanding the nature of CKD in sub-Saharan Africa.
Introduction
Chronic kidney disease (CKD) is an important global public health problem—estimated to
affect 10% of the world’s population [1]. In the United States, African Americans have several
fold higher rates of kidney failure than European Americans [2, 3]. Individuals living in sub-
Saharan Africa may have a heightened CKD risk similar to African Americans due to shared
genetic susceptibility, such as that arising from apolipoprotein L1 (APOL1) gene risk variants
and sickle cell trait [4–7]. CKD risk may be further exacerbated by HIV infection and its treat-
ment [8], the rising prevalence of hypertension [9], and diabetes [10], as well as the use of
potentially nephrotoxic traditional herbal medicines [11–13]. In sub-Saharan Africa, life-sav-
ing renal replacement therapy (dialysis or kidney transplantation) is not readily available, and
consequently, those who progress to end-stage renal disease (ESRD) die prematurely. For the
few who obtain access to renal replacement therapy, the cost often represents an enormous
financial burden on individuals and their families [14, 15]. Therefore, CKD has far-reaching
implications for the health and welfare of people living in this region.
However, little is known regarding CKD and its epidemiology in sub-Saharan Africa. The
existing literature is limited by small sample sizes and lack of representation of participants
from rural areas where the vast majority of the population resides [16]. A recent systematic
review of CKD epidemiology in sub-Saharan Africa concluded that the currently published
studies are mostly of low quality [17]. To improve our understanding of CKD in sub-Saharan
Africa, we investigated the prevalence of CKD and associated risk factors in a representative
community-based sample of rural East Africans.
Methods
Design and study population
This is a population-based cross-sectional study leveraging the infrastructure of the Sustainable
East Africa Research in Community Health (SEARCH, NCT01864603) trial [18]. SEARCH
was a 32-community cluster-randomized controlled trial with 355,848 participants living in 10
communities in eastern Uganda, 10 in southwestern Uganda and 12 in western Kenya [18]. In
each of the 32 rural communities, a house-to-house census enumeration of household mem-
bers was conducted from 2013 to 2014, followed by mobile 2-week multi-disease community
health campaigns, which was then followed by home-based testing for non-participants (Fig
1). Participants underwent screening for HIV, hypertension and diabetes. HIV-positive per-
sons and those screening positive for hypertension or diabetes were then referred for diagnosis
and treatment. Repeat population-based testing was conducted annually in intervention com-
munities and again in all communities among individuals who had not moved away at study
close in 2016–2017 (87%). SEARCH found that a multi-disease, community-based approach
to universal HIV test-and-treat approach reduced HIV incidence and improved community
health at a population level [18].
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To estimate the prevalence of CKD and understand its risk factors in rural East Africa, we
conducted a home-based sub-study (named SEARCH-CKD) during parent study year 3
(2016–2017). We utilized a sampling framework (established by the parent study in 2013)
where 100 households with at least one HIV-positive adult and 100 households without any
HIV-positive adults were randomly selected to participate in each study community [19]. For
the SEARCH-CKD sub-study, one HIV-positive adult was randomly selected from HIV-
positive households, and one HIV-negative adult was randomly selected from HIV-negative
households. During SEARCH-CKD specific home visits, participants underwent a health sur-
vey with emphasis on potential CKD risk factors as well as blood and urine sample collection
at their household. The SEARCH CKD sub-study supported the survey and assessments of
kidney health including serum creatinine and dipstick urinalysis which were not part of the
parent SEARCH study (Fig 1).
Kidney function assessments
Collected blood samples were transported to a local processing center. After processing, serum
samples were then transferred to a central laboratory in each of the three study regions (eastern
Uganda, southwestern Uganda and western Kenya) where serum creatinine was measured by
the Jaffe method, traceable to isotope dilution mass spectrometry (IDMS) reference on the
Cobas Integra 400 Plus (Roche Diagnostics, South San Francisco, CA, USA) and DRI-CHEM
NX500i (Fujifilm, Tokyo, Japan) platforms in Uganda and Kenya, respectively. The resultant
standardized serum creatinine values were used to estimate glomerular filtration rate (eGFR)
using the CKD-EPI equation [20], without the black race coefficient given concerns that this
may misclassify Africans [21–23].
We also conducted sensitivity analysis using the CKD-EPI equation with the black race
coefficient [20].
Determination of proteinuria
Urine dipstick analysis was performed using Uriscan Gen 10 Healgen URS-10T strips (Heal-
gen Scientific, LLC, Bellaire, TX, USA) in Uganda, and Uriscan SGL strips (Biosys Laborato-
ries, Inc., South Pasadena, CA, USA) were used in Kenya. Dipstick proteinuria results were
interpreted by trained study personnel as “negative,” “trace,” “1+”, “2+” or “�3+”.
Fig 1. Timeline and study activities for the sustainable East Africa research in Community Health (SEARCH) study sites, and SEARCH-CKD
sub-study.
https://doi.org/10.1371/journal.pone.0229649.g001
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Additional dipstick urinalysis abnormalities
We also gathered concurrent data on dipstick urinalysis hematuria and leukocyte esterase pos-
itivity (urine dipstick trace or greater). To reduce the chances of urinalysis abnormalities sim-
ply reflecting urinary tract infections, we did not count cases of leukocyte esterase positivity in
which nitrite was also positive during the analysis (only 5% of dipstick urinalysis positive for
leukocyte esterase were also positive for nitrite).
CKD prevalence
We defined CKD as an eGFR <60 mL/min/1.73m2 or presence of proteinuria (1+ or greater
dipstick proteinuria). Individuals with CKD were further classified into stages 1–5 according
to the 2012 Kidney Disease: Improving Global Outcomes [24] CKD guidelines: Stage 1: eGFR
�90mL/min/1.73m2 and proteinuria; stage 2: eGFR 60–89 mL/min/1.73m2 and proteinuria;
stage 3–5: eGFR<60 ml/min/1.73m2 regardless of proteinuria [25].
Exposures
Exposures of interest including hypertension, diabetes mellitus, and HIV infection were ascer-
tained at the parent SEARCH baseline (2013–2014) and follow-up (2016–2017) visits (Fig 1)
[18]. Blood pressures were measured using automated oscillometric devices. Hypertension
was defined as a systolic blood pressure�140 mm Hg or diastolic blood pressure�90 mm Hg
or self-reported current use of anti-hypertensive medications [26]. Participants who met crite-
ria for hypertension during initial blood pressure measurement underwent two repeat mea-
surements one minute apart to confirm the diagnosis of hypertension. Glucose was measured
using a finger-prick point-of-care non-fasting random blood glucose test (Optium-Abbott,
Alameda, CA, USA). Diabetes mellitus was defined as a random blood sugar >200 mg/dL
(11.1 mmol/L) [26]. HIV serostatus was determined by serial testing algorithms using point-
of-care testing devices as previously described [18]. Approximately 2% of our study partici-
pants were missing measurements for hypertension, diabetes mellitus, or HIV.
Additional exposures including self-reported use of nonsteroidal anti-inflammatory drugs
(NSAIDs) [27] and traditional herbal medicines [28], were ascertained through questionnaires
administered during the SEARCH-CKD sub-study home visits. Key additional factors that
were captured included household wealth index/score (categorized as quintiles) [29], educa-
tion (no formal education, primary school, or secondary school and beyond), and health habits
including smoking status (never, current, or former) and current alcohol usage (any vs. none).
Due to difficulty of obtaining height and weight during the study, 25.4% of our participants
were missing body mass index (BMI) data. Therefore, we did not include this variable in our
main analysis but conducted a sensitivity analysis among a subset of participants with available
BMI data.
Statistical analysis
We summarized the distribution of our exposures, outcomes and covariates overall, and by
study region (eastern Uganda, southwestern Uganda, and western Kenya). Age was catego-
rized into 18–29, 30–44, 45–59 and� 60 years at the ‘time of eGFR and proteinuria measure-
ment. To estimate the population-level prevalence of CKD and understand its associated risk
factors, we used inverse probability of weighting to account for the sampling of households
within each community and to adjust for incomplete ascertainment of CKD outcomes (i.e.
serum creatinine and dipstick urinalysis) among selected participants [30, 31]. The household
selection probability was estimated using empirical proportions specific to each community,
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and the probability of outcome measurement among selected participants was estimated with
logistic regression controlling for age, gender, HIV serostatus, relationship to head of house-
hold, and region.
With these weights, we used multivariable log-link Poisson regression models with robust
standard errors to estimate the adjusted CKD prevalence ratios [32]. Sociodemographics;
health habits; history of diabetes, hypertension, or HIV; and use of NSAIDs or traditional
herbal medicines have all been previously reported to be associated with CKD [8, 27, 28, 33],
and thus were included a priori in in the regression models. A P-value <0.05 indicated statisti-
cal significance. Stata version 15 (StataCorp, College Station, Texas, USA) was used for all
analyses.
Ethics
Institutional review boards of Makerere University, Uganda National Council of Science and
Technology (Kampala, Uganda), Kenya Medical Research Institute (Nairobi, Kenya), and the
University of California, San Francisco (San Francisco, CA, USA) approved the study protocol.
All participants provided signed informed consent in their preferred language.
Results
Population characteristics
The SEARCH-CKD sub-study completed home-visits on 3,686 residents from 22 rural com-
munities in Uganda and Kenya. Ten communities from the parent SEARCH study were not
included due to resource limitations, and 223 participants (6%) were missing serum creatine
or urinalysis results (S1 Table). Table 1 shows underlying population characteristics of adults
residing in rural Uganda and Kenya based on weighted SEARCH-CKD participants. The esti-
mated mean age of these adults living in rural East Africa was 38 (standard error [SE] 0.4)
years, and 52.4% (95% confidence interval [CI] 49.7–55.1%) were women. The population-
weighted prevalence of HIV, diabetes and hypertension were, 9.4% (95% CI 8.5–10.5%), 3.8%
(95% CI 2.9–4.8%) and 16.9% (95% CI 15.2–18.8), respectively. NSAID and traditional medi-
cine use was estimated to be 48.4% (95% CI 45.7–51.0%) and 27.9% (95% CI 25.6–30.3%),
respectively (with regional variations as shown in Table 1).
Proteinuria and eGFR
The estimated population-based prevalence of proteinuria was 5.4% (95% CI 4.4–6.6%). Pro-
teinuria prevalence was estimated to be highest in eastern Uganda at 11.2% (95% CI 8.9–
13.9%), compared to 3.5% (95% CI 1.9–6.4%) in southwestern Uganda and 1.4% (95% CI 0.8–
2.3%) in western Kenya, respectively (Table 2).
We estimated that the vast majority of individuals in East Africa (98.3%) have an eGFR
�60 ml/min/1.73 m2, with a weighted mean eGFR of 108 ml/min/1.73 m2 (SE 0.5).
Prevalence of CKD
The estimated population-weighted prevalence of CKD was 6.8% (95% CI 5.7–8.1%). How-
ever, the prevalence varied greatly by region, with eastern Uganda having the highest preva-
lence at 12.5% (95% CI 10.1–15.4%) compared with 3.9% (95% CI 2.2–6.8%) in southwestern
Uganda and 3.7% (95% CI: 2.7–5.1%) in western Kenya (Table 2). We estimated that of the
individuals with CKD in this region, the majority (75.8%) have stage 1 or 2, while 24.2% have
stage 3–5 CKD.
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Risk factors for prevalent CKD
In our univariable analyses, the factors most strongly associated with prevalent CKD were
being older, residence in eastern Uganda, lack of formal education, past smoking status and
hypertension (Table 3).
In our fully adjusted multivariable model, age�60 years (adjusted prevalent ratio [aPR] =
3.5 [95% CI 1.9–6.5] compared with age 18–29), and residence in eastern Uganda (aPR = 3.9
[95% CI 2.6–5.9]) remained strongly associated with prevalent CKD. While HIV seropositivity
was also associated with prevalent CKD in the multivariable model (aPR = 1.6 [95% CI 1.1–
2.1]), there were no significant associations between hypertension, diabetes, NSAIDs or tradi-
tional medicine use with prevalent CKD (Table 3).
Table 1. Population characteristics of adults in rural East Africa based on weighted SEARCH-CKD participants.
Eastern Uganda N = 1169 Southwestern Uganda N = 974 Western Kenya N = 1543 Total N = 3686
% (95% CI) % (95% CI) % (95% CI) % (95% CI)
Female 51.2 (46.4–56.0) 51.7 (45.9–57.4) 54.2 (50.5–57.8) 52.4 (49.7–55.1)
Age categories
18–29 46.3 (41.4–51.3) 34.3 (28.6–40.5) 31.0 (27.4–34.9) 37.3 (34.5–40.2)
30–44 26.6 (23.0–30.5) 37.1 (31.8–42.6) 37.9 (34.6–41.4) 33.7 (31.3–36.2)
45–59 17.4 (14.6–20.5) 18.3 (15.1–22.0) 17.4 (15.3–19.8) 17.7 (16.1–19.4)
� 60 9.7 (7.8–12.1) 10.3 (8.0–13.2) 13.6 (11.7–15.7) 11.3 (10.1–12.6)
Education level
No formal education 16.7 (13.8–19.9) 14.3 (11.6–17.5) 4.7 (3.7–6.0) 11.6 (10.3–13.1)
Primary school 59.6 (54.8–64.3) 59.0 (53.3–64.4) 82.1 (79.1–84.7) 67.6 (65.0–70.1)
Secondary school and beyond 23.7 (19.5–28.6) 26.8 (21.8–32.4) 13.2 (10.8–16.1) 20.8 (18.5–23.3)
Wealth Index/score⟘
1st quintile 14.1 (11.5–17.0) 21.6 (17.6–26.3) 12.2 (9.9–14.8) 15.6 (13.8–17.4)
2nd quintile 19.5 (16.1–23.3) 22.0 (17.7–27.0) 12.2 (10.1–14.8) 17.6 (15.6–19.7)
3rd quintile 21.1 (17.3–25.6) 19.3 (15.2–24.2) 22.1 (19.3–25.2) 21.0 (18.8–23.3)
4th quintile 25.0 (20.8–29.6) 15.2 (11.7–19.7) 24.0 (21.1–27.1) 21.8 (19.7–24.1)
5th quintile 20.4 (16.6–24.8) 21.9 (17.1–27.6) 29.5 (26.4–32.9) 24.1 (21.8–26.6)
Farmer 67.4 (62.2–72.3) 66.1 (60.1–71.6) 47.8 (44.4–51.2) 59.9 (57.2–62.5)
Tobacco use
Current 2.5 (1.6–3.9) 10.3 (7.3–14.4) 4.7 (3.6–6.3) 5.6 (4.5–6.9)
Past 2.7 (1.6–4.6) 11.2 (8.4–14.7) 3.9 (2.7–5.4) 5.6 (4.5–6.8)
Any current alcohol use 13.4 (10.3–17.2) 18.9 (14.2–24.6) 3.5 (2.4–5.1) 11.3 (9.4–13.5)
Body Mass Index
Underweight (< 18.5 kg/m2) 19.7 (15.6–24.7) 15.8 (11.7–21.0) 13.7 (11.1–16.9) 16.5 (14.3–19.0)
Normal (18.5–24.9 kg/m2) 62.8 (57.6–67.8) 66.0 (60.2–71.3) 71.2 (67.4–74.8) 66.6 (63.8–69.4)
Overweight (25.0–29.9 kg/m2) 14.0 (11.1–17.5) 14.6 (11.3–18.7) 11.7 (9.5–14.4) 13.4 (11.7–15.3)
Obese (�30.0 kg/m2) 3.5 (2.2–5.5) 3.6 (2.2–6.1) 3.3 (2.2–4.9) 3.5 (2.7–4.5)
HIV-positive 3.1 (2.1–4.5) 6.9 (5.2–9.1) 17.6 (15.8–19.6) 9.4 (8.5–10.5)
Diabetes mellitus 4.2 (2.7–6.6) 5.8 (4.1–8.1) 1.7 (1.1–2.7) 3.8 (2.9–4.8)
Hypertension 18.8 (15.7–22.3) 20.6 (16.8–25.1) 12.3 (10.4–14.6) 16.9 (15.2–18.8)
Any NSAID use over the previous 90 days 33.9 (29.5–38.6) 49.2 (43.5–55.0) 61.7 (58.1–65.1) 48.4 (45.7–51.0)
Any traditional medicine use over the previous 90 days 22.3 (18.9–26.2) 43.7 (38.2–49.4) 20.7 (17.9–23.8) 27.9 (25.6–30.3)
⟘Wealth index/score (divided in quintiles) was calculated using principal components analysis based on ownership of livestock and other household items items [29].
NSAID: nonsteroidal anti-inflammatory drugs
https://doi.org/10.1371/journal.pone.0229649.t001
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Table 2. Prevalence of Kidney function and proteinuria categories, by region and overall.
Eastern Uganda Southwestern Uganda Western Kenya All
Prevalence, % (95% CI) Prevalence, % (95% CI) Prevalence, % (95% CI) Prevalence, % (95% CI)
eGFR� 90 79.9 (76.3–83.0) 87.7 (84.3–90.4) 79.8 (77.3–82.1) 82.1 (80.3–83.8)
eGFR 60–89 18.6 (15.5–22.1) 11.8 (9.1–15.1) 17.5 (15.4–19.9) 16.2 (14.7–18.0)
eGFR < 60 1.6 (0.8–3.0) 0.5 (0.2–1.5) 2.6 (1.8–3.8) 1.7 (1.2–2.3)
Proteinuria 11.2 (8.9–13.9) 3.5 (1.9–6.5) 1.4 (0.8–2.3) 5.4 (4.4–6.6)
CKD
eGFR < 60 or proteinuria 12.5 (10.1–15.4) 3.9 (2.2–6.8) 3.7 (2.7–5.1) 6.8 (5.7–8.1)
CKD: Chronic kidney disease
eGFR: estimated glomerular filtration rate in ml/min/1.73m2
https://doi.org/10.1371/journal.pone.0229649.t002
Table 3. Univariable and multivariable association of risk factors with prevalent CKD.
Unadjusted Prevalence Ratio (95% CI) Adjusted Prevalence Ratio (95% CI)
Region
Eastern Uganda 3.33 (2.29–4.86) 3.88 (2.56–5.89)
South West Uganda 1.03 (0.53–1.98) 1.16 (0.48–2.79)
Western Kenya Reference Reference
Female 1.25 (0.86–1.81) 0.98 (0.64–1.51)
Age (Years)
18–29 Reference Reference
30–44 1.03 (0.58–1.83) 1.15 (0.63–2.11)
45–59 2.05 (1.15–3.63) 1.92 (1.05–3.54)
� 60 3.66 (2.12–6.32) 3.52 (1.89–6.54)
Education level
No formal education 2.38 (1.28–4.45) 1.24 (0.52–2.95)
Primary school 1.12 (0.62–2.02) 1.11s (0.51–2.42)
Secondary school and beyond Reference Reference
Wealth Index
1st quintile (Least Wealth) Reference Reference
2nd quintile (Less Wealth) 1.02 (0.62–1.68) 1.08 (0.67–1.73)
3rd quintile (Middle Wealth) 0.71 (0.42–1.20) 0.69 (0.41–1.16)
4th quintile (More Wealth) 0.91 (0.52–1.59) 0.90 (0.52–1.56)
5th quintile (Most Wealth) 0.94 (0.55–1.62) 1.10 (0.59–2.06)
Farmer 1.41 (0.94–2.13) 0.87 (0.53–1.44)
Smoking status
Current smoker 1.20 (0.59–2.44) 1.32 (0.67–2.60)
Past smoker 1.79 (1.07–2.98) 1.68 (0.93–3.05)
Any alcohol use 0.82 (0.47–1.43) 0.64 (0.34–1.18)
HIV Positive 1.05 (0.79–1.39) 1.58 (1.11–2.24)
Diabetes 1.78 (0.85–3.72) 0.86 (0.35–2.11)
Hypertension 1.68 (1.17–2.41) 1.05 (0.74–1.50)
Any NSAIDs use 0.70 (0.49–1.00) 0.83 (0.57–1.22)
Any traditional medicine use 0.92 (0.61–1.39) 0.96 (0.62–1.51)
Multivariable model included region, demographics, wealth index, farming occupation, history of diabetes,
hypertension, HIV, use of NSAIDs and traditional herbal medicines
CKD: Chronic kidney disease. NSAID: nonsteroidal anti-inflammatory drugs
https://doi.org/10.1371/journal.pone.0229649.t003
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Notably, we estimated that two-thirds of individuals (65.8%) with CKD in East Africa did
not have HIV, diabetes or hypertension.
Other urine dipstick characteristics
Among the dipstick urinalyses, (N = 3463), 7.4% had hematuria and 12.2% had leukocyturia
(leukocyte esterase positive) without positive nitrite. Fig 2 shows the overlap between protein-
uria, hematuria and leukocyturia. Most participants with leukocyturia did not have hematuria
or proteinuria. There also was minimal overlap between hematuria and proteinuria.
Sensitivity analysis
In our sensitivity analysis using the CKD-EPI equation with the black race coefficient to esti-
mate GFR, 99% of individuals had an eGFR�60 ml/min/1.73 m2, with a mean eGFR of 126
ml/min/1.73 m2 (SE 0.6). Because most of the CKD cases we identified were based on protein-
uria, the overall population-weighted prevalence of CKD was very similar at 6.0% (95% CI 5.0–
7.3%). In terms of risk factors, observed patterns and strengths of associations were similar.
In our sensitivity analysis among a subset of participants with available BMI we observed that
being overweight was associated with CKD (aPR = 1.8 [95% CI 1.1–3.0] compared with normal
BMI). There was no association of being underweight nor obese with CKD (aPR = 0.9 [95% CI
0.6–1.4], and aPR = 1.8 [95% CI 0.7–4.3] respectively, when compared with normal BMI).
Discussion
The SEARCH-CKD study included 3,686 participants from 22 rural communities, spanning
three regions in two East African countries. To our knowledge, this study represents one of the
Fig 2. Venn diagram showing relationships between leukocyturia, proteinuria, and hematuria among
SEARCH-CKD participants with both serum creatinine and urine dipstick results (N = 3463).
https://doi.org/10.1371/journal.pone.0229649.g002
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largest population-based study of CKD in sub-Saharan Africa. Given an estimated mean age of
38 years among these adults in East Africa, our finding of a community-based CKD prevalence
of 6.8% in this young population is concerning. Moreover, the prevalence of CKD varied
greatly by region, with more than a 3-fold higher prevalence in eastern Uganda. CKD preva-
lence was largely driven by a high prevalence of proteinuria, and most participants had pre-
served kidney function as estimated by the CKD-EPI equation.
Proteinuria has been shown repeatedly to be associated with increased risk of progression
to ESRD [33–36] and other adverse outcomes, including cardiovascular disease and premature
death [37–39]. Early detection of proteinuria, and management of its modifiable risk factors
may slow progression to more advanced stages of CKD, including ESRD. This is an attractive
strategy to decrease morbidity and mortality associated with advanced CKD in sub-Saharan
Africa, where access to renal replacement therapy is scarce [40–42].
Although comparing available studies is difficult due to differences in CKD definition, our
results are consistent with two other community-based studies from East Africa, one from cen-
tral Uganda [43], and another from northern Tanzania [44]. These two studies yielded a simi-
lar prevalence of CKD (7–10%), which was also predominantly driven by proteinuria [43, 44].
In West and Central Africa, community-based CKD prevalence estimates have ranged from
6–19% [45–49], with highest prevalence reported in Southwestern Nigeria [49]. However,
these studies were limited to one geographical region within each country. In contrast, the
SEARCH-CKD study extends our knowledge by examining multiple communities in more
than one country using a pre-defined research protocol, and shows that even within a country,
there may be significant differences in CKD prevalence. Future efforts to better understand
geographic variations in CKD prevalence may shed important light into disease pathophysiol-
ogy and identify promising strategies to mitigate the health burden of CKD.
It is interesting to speculate whether differences in the prevalence of CKD genetic risk fac-
tors across regions in sub-Saharan Africa may account for the differences in CKD prevalence.
For instance, studies conducted in sub-Saharan Africa have shown that the frequency of the
APOL1 risk variants, which significantly increase the risk of CKD, varies across the continent
[50]. Due to unique evolutionary pressures within sub-Saharan Africa, individuals living in
sub-Saharan Africa exhibit remarkable genetic diversity [51]. For example, while the APOL1
G1 and G2 risk variants confer protection specifically against Trypanosoma brucei (T.b.) rhode-
siense [4], Uganda is one of the few countries where both T.b. rhodesiense and T.b. gambiense
are endemic [52]. Therefore, individuals in different parts of East Africa may have variable
genetic susceptibility to CKD based on regional differences in environmental pressures, but
further studies are warranted.
While HIV remained an important CKD risk factor in this study, diabetes, hypertension,
use of NSAIDs and traditional herbal medicines were not associated with prevalent CKD in
our study. In fact, we estimated that two-thirds of individuals with CKD in East Africa do not
have traditional CKD risk factors such as HIV infection, hypertension or diabetes. Our popula-
tion is relatively young and would be expected to have lower prevalence of hypertension and
diabetes compared to an older population, and these risk factors may become more relevant to
CKD as the population ages. Currently, much remains to be unearthed about unique risk fac-
tors of CKD in East Africa. Candidate risk factors which merit study include environmental
exposures such as heavy metals [53, 54], endemic infections causing glomerulonephritis, and
acquired or congenital anatomic abnormalities. These risk factors may interact with genetic
risk factors enriched in sub-Saharan Africa—such as the APOL1 renal risk variants and sickle
cell trait [55, 56], or other yet to be identified genetic susceptibility loci. Furthermore, these
risk factors distribution may differ by geography, which can explain the geographic variation
in CKD prevalence observed in this study.
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A provocative (and somewhat surprising) finding we noted in the course of ascertaining
proteinuria in SEARCH-CKD was how commonly hematuria and leukocyturia (without con-
current positive nitrite) occurred in this young, community-representative population—being
seen in 7% and 12% of urine dipstick analyses, respectively. To our knowledge, the high preva-
lence of such dipstick urinalysis abnormalities among individuals in sub-Saharan African have
not been previously reported. The etiologic reasons are not clear. Given the high prevalence
and in the absence of positive nitrite by dipstick, simple bacterial urinary tract infection is
unlikely to be the explanation. These abnormalities may reflect underlying parenchymal renal
disease such as glomerulonephritis or interstitial nephritis, but we did not count them as CKD
cases as we could not rule out alternative explanations such as genitourinary tuberculosis. Of
note, some patients with CKD of unknown cause in agricultural communities (such as Meso-
american nephropathy, Uddanam nephropathy or Sri Lankan nephropathy) present with leu-
kocyturia and hematuria without proteinuria [57]. These patients have been reported to have
acute or chronic interstitial nephritis on renal biopsy [58–60]. However, to our knowledge,
there have been few studies of this among people living in rural Uganda and Kenya.
The major strengths of our study are, large sample size that included 3 distinct regions in
two countries, population-based, and comprehensively documents the prevalence of CKD and
risk factors in rural East Africa. We probed for CKD using serum creatinine as well as urine
protein (and also assessed for other urinary abnormalities such as hematuria and leukocyturia
which could also reflect intrinsic renal disease). We also acknowledge several limitations. First,
given the study’s cross-sectional design, we could not confirm the persistence of abnormal renal
parameters with repeat measurements. Second, dipstick urinalysis interpretations were not cen-
tralized or automated. However, all research assistants received extensive training and supervi-
sion during data collection, and quality assurance/control procedures were conducted daily
before all measurements. Therefore, we believe that our dipstick urinalysis findings are robust.
Identical dipstick kits were used in eastern Uganda and southwestern Uganda so it is unlikely
that systematic errors in laboratory assessments could explain the observed differences in preva-
lence of proteinuria between those two regions. Third, diabetes prevalence may have been
underestimated given the lack of fasting blood glucose or hemoglobin A1c measurements.
Fourth, serum creatinine measurements were also not centralized; however, each of the labora-
tories conducted daily internal calibration and paid particular attention to this aspect of quality
control. Finally, we did not probe for symptoms of urinary tract infection (e.g. dysuria) or back
pain which potentially could shed light on the reasons for dipstick urinalysis abnormalities [57].
In conclusion, we observed a high prevalence of CKD, with a considerable geographic vari-
ation in a young population of rural East Africans. The high CKD prevalence was largely
driven by proteinuria and provides opportunities for early interventions to delay progression
of kidney disease to ESRD in an area with limited renal replacement therapy. While CKD is
associated with HIV infection, two-thirds of CKD cases appear without an obvious CKD risk
factor, and leukocyturia and hematuria were common. Our data highlight the urgent need for
further research to better understand cause and distribution of CKD in this region.
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